The Electrolyte-Gated Organic Field Effect Transistors (EGOFETs) is an ideal candidates for the next generation of biosensors suitable for the detection and quantification of biological molecules due to its low operation potential (i.e. <1V) and the possibility to function in aqueous media. The principle of operation of these devices resides into the coupling which is established through the electrolyte between the gate electrode and the semi-conductive channel, resulting in a large effective capacitance which significantly lowers the operational voltage with respect to the traditional OFETs. Modifications in the structures of the relevant technological interfaces, namely gate/electrolyte and electrolyte/semiconductor (e.g. binding events), induce a change in capacitance, which increases the overall sensitivity of the device. Functionalizing the gate electrode with specific antibodies or functional groups, the EGOFETs can sense their binding with the target antigens present inside the electrolyte.
A lab-on-chip device is obtained by the integration between an EGOFET and a microfluidic channel featuring perfusion controlled by a peristaltic pump. The configuration with multiple top gate electrodes allows statistical robustness as well as continuous monitoring of the stability of the organic electronic device. Due to its low cost and the possibility of integration in a high-scale industrial production, this device has a big potential to be used in clinic environment, with possible application within an early diagnosis of cancer, Alzheimer or other inflammatory diseases.